Ad Scientiam and Ceres Brain Therapeutics join forces to develop innovative digital biomarkers in Creatine Transporter Deficiency.

We are thrilled to announce that Ad Scientiam and Ceres Brain Therapeutics are launching a joint research program to develop new digital biomarkers for Creatine Transporter Deficiency Syndrome. Ad Scientiam, a global leader in digital biomarkers and Ceres Brain Therapeutics, a biotech company developing a drug candidate for a rare neurological disease, the Creatine Transporter Deficiency Syndrome, join forces to develop new digital biomarkers to optimize future clinical trials.

Share